Resumen de Cancer incidence in Spain, 2015

Jaume Galceran Padrós, A. Ameijide, M. Carulla, Antonio Mateos Ramos, José Ramón Quirós García, D. Rojas, A. Alemán, A. Torrella, M. Chico, Marisa Vicente Raneda, J. M. Díaz García, Nerea Larrañaga Larrañaga, Rafael Marcos Gragera, María José Sánchez Pérez, Josefina Perucha González, Paula Franch Sureda, Carmen Navarro Sánchez, Eva Ardanaz Aicua, Jàmnica Bigorra, María Pilar Rodrigo Val, Rafael Peris Bonet

• Purpose Periodic cancer incidence estimates of Spain from all existing population-based cancer registries at any given time are required. The objective of this study was to present the current situation of cancer incidence in Spain.

  Methods The Spanish Network of Cancer Registries (REDECAN) estimated the numbers of new cancer cases occurred in Spain in 2015 by applying the incidence-mortality ratios method. In the calculus, incidence data from population-based cancer registries and mortality data of all Spain were used.

  Results In 2015, nearly a quarter of a million new invasive cancer cases were diagnosed in Spain, almost 149,000 in men (60.0%) and 99,000 in women. Globally, the five most common cancers were those of colon–rectum, prostate, lung, breast and urinary bladder. By gender, the four most common cancers in men were those of prostate (22.4%), colon–rectum (16.6%), lung (15.1%) and urinary bladder (11.7%). In women, the most common ones were those of breast (28.0%), colon–rectum (16.9%), corpus uteri (6.2%) and lung (6.0%). In recent years, cancer incidence in men seems to have stabilized due to the fact that the decrease in tobacco-related cancers compensates for the increase in other types of cancer like those of colon and prostate. In women, despite the stabilization of breast cancer incidence, increased incidence is due, above all, to the rise of colorectal and tobacco-related cancers.

  Conclusion To reduce these incident cancer cases, improvement of smoking control policies and extension of colorectal cancer screening should be the two priorities in cancer prevention for the next years.